Browse News
Filter News
Found 23 articles
-
Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results
2/6/2024
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.
-
ImmunoBrain Checkpoint Appoints Dr. Sanjay Keswani as Chief Executive Officer
1/22/2024
ImmunoBrain Checkpoint Inc. today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.
-
Israel-based cancer immunotherapy company Compugen will receive $60 million upfront from Gilead for the license to its antibody, which blocks the interaction between the IL-18 binding protein and IL-18.
-
Gilead Sciences Announces Third Quarter 2023 Financial Results
11/7/2023
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.
-
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
9/26/2023
In a major achievement, Avalo Therapeutics proudly announces the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance Corporation.
-
Gilead Sciences Announces Second Quarter 2023 Financial Results
8/3/2023
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter of 2023.
-
Gilead Sciences Announces First Quarter 2023 Financial Results
4/27/2023
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2023.
-
4 Questions With Flavius Martin: Enhancing Innovation by Expanding Gilead’s Research Footprint
2/15/2023
Innovation is at the core of Gilead's 35-year history of life-changing medicines. Through bold and transformative science, Gilead has developed therapies that have brought about a cure for hepatitis C, helped to transform the treatment and prevention of HIV and provided breakthrough therapies for people with cancer.
-
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
2/2/2023
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2022.
-
Gilead Sciences Announces Third Quarter 2022 Financial Results
10/27/2022
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2022.
-
Gilead Sciences Completes Acquisition of MiroBio
9/20/2022
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio, a privately held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for approximately $405 million in cash.
-
Biogen expects to lay off a potential 1,000 staffers in an effort to cut about $1 billion in costs, according to The Boston Globe, while 10x Genomics and Talis Biomedical also cut staff.
-
A recent report predicts multiple acquisitions are set to be announced in the second half of the year, particularly by companies that have strong revenue streams from COVID-19 products.
-
Gilead snapped up U.K.-based MiroBio in a $405 million deal that will bring its checkpoint agonists and discovery platform under Gilead's umbrella.
-
Gilead Sciences to Acquire MiroBio
8/4/2022
Gilead Sciences, Inc. today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments.
-
This week money went towards more advanced rounds of financing for drugs and technology that have already shown a lot of promises.
-
Innovation community at The Oxford Science Park expands further as companies move into the Hayakawa Building
5/16/2022
The innovation community at The Oxford Science Park, one of Europe's leading locations for science and technology companies, continues to expand as firms move into the newly refurbished Hayakawa Building.
-
BioSpace Movers & Shakers, March 11
3/11/2022
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers -
MiroBio Continues Expansion of Executive Leadership Team with Key Appointments to Advance Development of Checkpoint Agonist Antibodies for Autoimmune Disease
3/8/2022
MiroBio, a biotechnology company advancing checkpoint agonist therapies to restore immune balance, announced two key additions to its leadership team.
-
BioSpace Movers & Shakers, Sept. 24
9/24/2021
Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.